We are advancing our lead program for multiple serious forms of heart failure, with an initial focus on non-ischemic dilated cardiomyopathy (DCM).
TLT-101 is our lead precision medicine program designed to target the underlying biology of failing heart muscle.
We have generated extensive preclinical datasets, spanning 7 comprehensive efficacy and safety studies, across 3 different species, including 2 independent large animal models of acquired heart failure. These studies have demonstrated an exceptional efficacy and safety profile in gold-standard translational models of DCM with the ability to:
TLT-101 is in IND-enabling development for non-ischemic DCM with an anticipated IND filing in 2025